Losamax H Tablet
Losartan Potassium + Hydrochlorothiazide 50/12.5 and 100/25 mg Tab
Losamax-H 100/25:: Each tablet contain Losartan Potassium USP 100 mg and Hydrochlorothiazide BP 25 mg.
Losamax-H is indicated for the treatement of essential hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide alone. It is also indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
Hypertension: The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily. For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered. No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis. A lower dose should be considered for patients with a history of hepatic impairment. Reduction in the Risk of Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: The usual starting dose is 50 mg of Losartan once daily. A low dose of hydrochlorothiazide should be added and/or the dose of Losartan should be increased to 100 mg once daily based on blood pressure response. Heart Failure: The initial dose of Losartan in patients with heart failure is 12.5 mg once daily. The dose should generally be titrated at weekly intervals (i.e., 12.5 mg daily, 25 mg daily, 50 mg daily) to the usual maintenance dose of 50 mg once daily, as tolerated by the patient. Losartan is usually given in combination with diuretics and digitalis. Renal Protection in Type 2 Diabetic Patients with Proteinuria: The usual starting dose is 50 mg once daily. The dose may be increased to 100 mg once daily based on blood pressure response. Losartan may be administered with other antihypertensive agents (e.g., diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycaemic agents (e.g., sulfonylureas, glitazones and glucosidase inhibitors)